BIO-B vs EHC

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong balance sheet (Current Ratio: 5.44, Debt/Equity: 0.21), the company is unprofitable (Profit Margin: -26.43%, ROE: -9.50%) and lacks meaningful valuation metrics due to negative earnings. While quarterly earnings have beaten estimates 3 out of 4 times recently, revenue growth is nearly flat (0.50% YoY), and long-term price performance remains deeply negative (-47.0% over 5 years). The absence of Altman Z-Score and Graham Number prevents a full value assessment, but current fundamentals do not support a bullish stance.

EHC presents a stable financial profile with a Piotroski F-Score of 4/9 and a significant valuation gap between its defensive Graham Number ($55.18) and growth-based Intrinsic Value ($163.72). The company exhibits exceptional operational efficiency with an ROE of 24.82% and a highly attractive PEG ratio of 0.41, suggesting the stock is undervalued relative to its earnings growth. While insider sentiment is bearish and technical trends are currently weak, the long-term fundamental trajectory is supported by a 25-quarter track record of consistent earnings beats. The current price of $101.98 represents a reasonable entry point given the analyst target of $142.73.